A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
about
Axitinib for the management of metastatic renal cell carcinomaReduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigmSafety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials.Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study.Regorafenib: from bench to bedside in colorectal cancer.Development of second-generation VEGFR tyrosine kinase inhibitors: current status.Intra-Laboratory Pre-Validation of a Human Cell Based in vitro Angiogenesis Assay for Testing Angiogenesis Modulators.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours.Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursRole of bevacizumab in colorectal cancer growth and its adverse effects: a review.Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?Clinical pharmacology of axitinib.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo.Thromboembolic Events Associated with Bevacizumab plus Chemotherapy for Patients with Colorectal Cancer: A Meta-Analysis of Randomized Controlled Trials.Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies.Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.Vascular endothelial growth factor (VEGF) antibody significantly increases the risk of hand-foot skin reaction to multikinase inhibitors (MKIs): A systematic literature review and meta-analysis.
P2860
Q24613720-188036D2-9B5F-4E26-84E6-C78898245307Q30317831-C7B219BB-3435-43E2-8735-E5C7FA0A03E0Q30453423-D26D50E2-505F-4B10-B01C-8FB0DF0A20D6Q31127134-BC789F6E-CCDB-4C04-B411-2815600DAFFCQ33409913-86FA766A-7B47-4898-815B-680367E6E04EQ34343524-294B0806-B356-4D5A-8758-3255AED8E506Q34616440-0076ADF7-47E4-46E8-B259-D7D3052657CBQ35100891-164EAE0F-D33E-4353-BDF1-BC540168A21FQ35923178-61AB5BC4-A7F2-4734-B72D-02F1A04A1329Q36387806-99238403-1A50-4BCC-811D-FDF86F8A8B0BQ36387910-0C941192-AB03-4F6B-93F9-EF8599C4214EQ37102447-5EABCB93-DB5D-4F20-A3EA-C17CC08C9A2AQ37594384-6673C917-5C60-4070-B89D-0A65EBBA2EE7Q37799821-B6058D81-3F50-441C-9F2D-A26E050DCEE2Q37921797-21440CB6-96D4-4695-AF56-ADB1922992D2Q38107175-5345918E-DA20-4614-B8D5-87095628C3F9Q38365290-165DA49D-9757-4308-8043-0529B9EF9316Q38514440-18CED2AD-EBF2-4A09-B91E-DFA36449ABC3Q38552109-F5062402-301C-448B-8CEB-4BD0E0C9C841Q38997536-45B2AC2B-B8C0-46DB-9654-8A3534117C74Q40975248-F653DECF-3A0F-492A-AAED-62CE7EA26FA6Q41872813-BD82EB8D-0B8F-41BA-B339-B3A5CCF3225AQ42770955-62D8AF73-BD16-4A11-8284-BF3A1D4B14A4Q43515124-39745E27-2B64-4A7A-82BD-17D87B8BA096Q45276051-84305D90-B66D-4400-B72D-65F57C994D06Q47578424-E7A49345-4A0F-4238-8CA4-B1D753FF414CQ50091855-AD1B1C6A-4259-4C76-94AA-9122AEDF54C4Q51356317-7009878A-355E-4D6C-8122-28CC7DAA1217Q52654231-B0CC16EC-640E-43C4-8FB4-EAE1B273D6C4
P2860
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
A phase I study of axitinib (A ...... cancer and other solid tumors.
@en
A phase I study of axitinib
@nl
type
label
A phase I study of axitinib (A ...... cancer and other solid tumors.
@en
A phase I study of axitinib
@nl
prefLabel
A phase I study of axitinib (A ...... cancer and other solid tumors.
@en
A phase I study of axitinib
@nl
P2093
P921
P356
P1433
P1476
A phase I study of axitinib (A ...... cancer and other solid tumors.
@en
P2093
M Tortorici
R C Trowbridge
R E Burgess
R L Robles
V Abhyankar
P304
P356
10.1093/ANNONC/MDP489
P577
2009-11-25T00:00:00Z